Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-11-06
2009-08-25
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C435S320100, C435S455000, C536S023500, C536S024100
Reexamination Certificate
active
07579330
ABSTRACT:
This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having the melanoma differentiation associated gene (mda-7) or the gene product of the melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5643761 (1997-07-01), Fisher et al.
patent: 5710137 (1998-01-01), Fisher
patent: 6190909 (2001-02-01), Levinson et al.
patent: 6355622 (2002-03-01), Fisher
patent: 6511676 (2003-01-01), Boulikas
patent: 6720408 (2004-04-01), Fisher et al.
patent: 6855686 (2005-02-01), Fisher
patent: WO95/11986 (1995-05-01), None
patent: WO98/06441 (1998-02-01), None
patent: WO00/55310 (2000-09-01), None
patent: WO01/05437 (2001-01-01), None
patent: WO 01/34130 (2001-05-01), None
Rudinger, 1976, Peptide Hormones, Edited by Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Verma, Sep. 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki, 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
Rudinger “Peptide Hormones” (1976) Edited by Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al. “A Single Amino Acid Substitution Results In A Retinoblastoma Protein Defective In Phosphorylation and Oncoprotein Binding” (1990)Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al. “From Genes To Protein Structure and Function: Novel Applicatiosn of Computational Approaches In the Genomic ERA” (2000)Trends in Biotech, vol. 18, p. 34-39.
Deonarain “Liquid-Targeted Receptor-Mediated Vectors For Gene Delivery” (1998)Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Verma et al. “Gene-therapy—Promises, Problems and Prospects” (Sep. 1997)Nature, vol. 389, pp. 239-242.
Eck et al. “Goodman & Gilman's The Pharmacological Basis of Therapeutics” (1996) McGraw-Hill, New York, p. 77-101.
Gorecki “Prospects and Problems of Gene Therapy: An Update:” (2001)Expert Opin. Emerging Drugs6(2): 187-198.
Cunningham et al. “Clinical and Logical Effects of an Intratumoral Injection of mda-7 (IL24; INGN 241) in Patients with Advanced Carcinoma: A Phase I Study” (2005)Mol. Ther. 149-159.
Lebedeva et al. “mda-7/IL 24: Exploiting Cancer's Achilles' Heel” (2005)Mol. Ther. 4-18.
Tong et al. “Intratumoral Injection of INGN 241, A Nonreplicating Adenovector Expressing the Melanoma-Dofferentation Associated Gene-7 (mda-7/IL24): Niologic Outcome in Advanced Cancer Patients” (2005)Mol. Ther. 160-172.
Introgen Therapeutics, Inc. Press release Jun. 7, 2004. Introgen Presents Final Data From INGN 241 Phase I Study, Demonstrating Clinical and Biologic Activity.
Chen, J. et al. “Tumor suppressor MDA-7/IL-24 selectively inhibits vascular smooth muscle cell growth and migration” (2003)Mol Ther. 8:220-229.
Fisher et al. “Mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory to the clinic” (2003)Cancer Biol. and Ther. 2:Suppl. 1, S23-37. 2003.
Introgen Therapeutics, Inc., Press release, Sep. 25, 2003. Publication shows Introgen's INGN 241 drug overcomes common cancer toxicity pathways.
Prochazkova et al. “Comparative study of apoptosis-detecting techniques: Tunel, apostain, and lamin B.” (2003)Biotechniques35(3):528-534.
Jiang et al. “Subtraction Hybridization Identifies A Novel Melanoma Differentiation Associated Gene, mda-7, Modulated During Human Melanoma Differentiation, Growth and Progression” (1995)Ongene11:2477-2488.
Barr et al. “Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus” 1994,Gene Ther., 1(1):51-8.
Calvo et al. “Adenovirus-mediated endostatin delivery results in inhibition of mammary glad tumor growth in C3(1)/SV40 T-antigen transgenic mice” 2002,Cancer Res., 62:3934-8.
Chen et al. “Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin” 2000,Hum. Gene Ther., 11(14):1983-96.
Heise et al. “Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy” 1999,Cancer Res., 59:2623-8.
Shi et al. “Noninvasive gene targeting to the brain” 2000,Proc. Natl. Acad. Sci. U.S.A., 97:7567-72.
Stratford-Perricaudet et al. “Widespread long-term gene transfer to mouse skeletal muscles and heart” 1992,J. Clin. Invest., 90:626-30.
Baker & Botts L.L.P.
Chen Shin-Lin
The Trustees of Columbia University in the City of New York
LandOfFree
Methods of treating various cancers using melanoma... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating various cancers using melanoma..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating various cancers using melanoma... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054773